Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

A Food and Drug Administration advisory committee is to meet Thursday to consider eliminating the use of Amgen's drugs Epogen and Aranesp, and the Johnson & Johnson drug Procrit for cancer patients with certain types of tumors or eliminating the use among all cancer patients, The New York Times reported.

The newspaper said eight clinical trials have suggested the drugs might make tumors worse or shorten the life of cancer patients. One FDA adviser last year called the drugs "Miracle-Gro for cancer."

Researchers said the anemia drugs are synthetic forms of a human hormone called erythropoietin, or Epo, that is involved in the production of red blood cells. Epo may encourage the growth of blood vessels that nourish tumors or may actually stimulate tumors directly, scientists said. Another theory is that Epo protects tumors from being destroyed by chemotherapy.

Amgen said it has not seen any convincing evidence Epo does anything but spur red blood cell production, the newspaper said.

Copyright 2008 by United Press International

Explore further: Rapamune approved for rare lung disease

Related Stories

Q&A: Why are antibiotics used in livestock?

11 hours ago

Wal-Mart, the world's biggest retailer, is the latest company to ask its suppliers to curb the use of antibiotics in farm animals. Here's a rundown of what's driving the decision: ...

Recommended for you

Rapamune approved for rare lung disease

2 hours ago

(HealthDay)—Rapamune (sirolimus) has been approved by the U.S. Food and Drug Administration to treat a rare, progressive lung disease that mostly affects women of childbearing age.

FDA warns of complications from facial fillers

3 hours ago

(HealthDay)—Soft tissue fillers used in cosmetic procedures can accidentally be injected into blood vessels in the face and cause serious harm, the U.S. Food and Drug Administration warns.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.